CEO Ricciardi Sells 5,850 Shares of Cognition Therapeutics Amid Quiet Portfolio Rebalance, Market Unchanged.
CEO Lisa Ricciardi’s recent 5,850‑share sale at $1.12 shows a deliberate portfolio rebalance, not panic, amid Cognition Therapeutics’ steady dementia‑treatment outlook.
3 minutes to read